GlaxoSmithKline jumps into myeloma with 'homemade' anti-BCMA drug Blenrep

GlaxoSmithKline | August 07, 2020

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began building its oncology pipeline “pretty aggressively,” as Axel Hoos, the company’s SVP of Oncology R&D, puts it. Those efforts have finally paid off with a new approval. But just how much remains to be seen, with analysts expecting "limited adoption" for the company's newcomer thanks to a Black Box warning for eye toxicity. The FDA late Wednesday green-lighted Blenrep—formerly known as belantamab mafodotin—a first-in-class antibody-drug conjugate for multiple myeloma patients who have already tried four other options, including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent.

Spotlight

Efficacy issues due to inadequate gastrointestinal (GI) absorption caused by insufficient aqueous solubility are encountered in up to 70% of new drugs in development. 1 Typically, in vitro analysis and preclinical studies are used to predict the behaviour of the drug in vivo.

Spotlight

Efficacy issues due to inadequate gastrointestinal (GI) absorption caused by insufficient aqueous solubility are encountered in up to 70% of new drugs in development. 1 Typically, in vitro analysis and preclinical studies are used to predict the behaviour of the drug in vivo.

Related News

KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development

KYAN Therapeutics, Inc. | September 24, 2020

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate Cancer. The low toxicity and metabolic stability of KYAN-001 indicates a better safety and tolerability profile than FDA approved pan-HDAC inhibitors which suffer from toxicity issues and side effects. KYAN-001 also uniquely inhibits HDAC4 nucleoshuttling to further drive its anti-cancer effects.

Read More

Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

Thermo Fisher | October 15, 2020

Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. The CTS Rotea system is the first Gibco instrument for cell therapy processing applications and facilitates workflows from research through GMP clinical development and commercial manufacturing. As of mid-2020, 675 clinical trials were underway globally for cell therapy and cell-based immune-oncology, according to the Alliance for Regenerative Medicine. Yet few cell therapies in development become commercially available due to several factors: safety and efficacy requirements, difficulties in transferring research protocols to manufacturing processes, lack of scalability of these therapies, high cost of facilities, labor and equipment, and complexity of the processes involved.

Read More

PHARMACY MARKET

McKesson Collaborates with Vanderbilt Health Rx Solutions to Expand Integrated Pharmacy Services

McKesson Corporation, Vanderbilt Health Rx Solutions | March 18, 2021

McKesson Corporation, a worldwide healthcare organization, reports another cooperation with Vanderbilt Health Rx Solutions (VHRxS), a public chief in specialty pharmacy technique and execution, to offer VHRxS's full suite of specialty pharmacy consulting services to McKesson's health system clients. This new, specialized offering from VHRxS will supplement the experience of McKesson, which has offered industry-driving pharmacy services for over 40 years, by bringing the skill of VHRxS, which was established by Vanderbilt University Medical Center to propel the mission of health systems specialty drug stores cross country. The new help will offer altered specialty pharmacy services and development procedures to emergency clinics and health systems in each period of their development. VHRxS's portfolio of strong specialty pharmacy consulting services will help health systems improve patient and supplier fulfillment while making new income transfers by fully coordinating pharmacy services into specialty centers. Scott Miller, president of McKesson Health Systems, shares, “Our teams work closely with customers to understand their challenges and this was a clear need for health systems addressing their specialty pharmacy capabilities. Along with our existing portfolio of services and solutions, this is one more way customers can achieve more for their hospitals and patients by creating new or strengthening existing revenue streams.” McKesson's pharmacy chiefs and the VHRxS group of experienced, involved counsels comprehend the requirements and difficulties of health system specialty drug stores. The groups have profound experience working with health systems altogether phases of development, from creating and carrying out starting specialty pharmacy development methodologies to improving existing activities to arrive at the following level. Jim Hayman, president of VHRxS and Chief Pharmacy Officer at Vanderbilt Health, states, “By collaborating with McKesson, we can better extend our expertise as a leading health system-based specialty pharmacy provider to help our peers. We know from experience that investing in your specialty pharmacy operations boosts patient and provider satisfaction, which reaps seen and unseen benefits many times over.” About McKesson Corporation McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful all for the better health of patients. About Vanderbilt Health Rx Solutions Vanderbilt Health Rx Solutions (VHRxS) is a national specialty pharmacy strategy and management company founded and operated by Vanderbilt University Medical Center (VUMC), Middle Tennessee’s largest private employer and the largest academic medical center in the Mid-South with over 2.5 million patient encounters annually. VHRxS uniquely and effectively addresses the specialty pharmacy needs of companies, hospitals and health systems through building patient-centered, clinically integrated specialty pharmacy programs in collaboration with health system clients and leading employers. Founded on VUMC’s historic global leadership in clinical pharmacology, best-in-class specialty pharmacy operations and employee health plan performance, VHRxS draws on years of hands-on experience creating and executing specialty pharmacy strategies to help clients build successful programs of their own.

Read More